Contact
QR code for the current URL

Story Box-ID: 1233899

CeGaT GmbH Paul-Ehrlich-Str. 23 72076 Tübingen, Germany http://www.cegat.com
Contact Ms Nora Zeller +49 7071 56544260
Company logo of CeGaT GmbH

CeGaT Introduces CancerMRD: Personalized and Non-Invasive Tumor Monitoring

(PresseBox) (Tübingen, )
CeGaT GmbH, a global provider of genetic diagnostics and sequencing services, proudly announces the launch of CancerMRD, a new service for the individualized monitoring of minimal residual disease (MRD) in patients with solid tumors. CancerMRD dynamically tracks changes in disease during therapy and detects recurrences earlier than conventional imaging methods. This non-invasive monitoring tool ultimately helps improve patient prognosis.

Overcoming a Key Challenge in Cancer Monitoring
Minimal residual disease remains a critical challenge in cancer care: Even after successful treatment, undetected tumor cells can persist in the body, increasing the risk of recurrence. These cells often evade conventional detection methods but release circulating tumor DNA (ctDNA) into the bloodstream, offering an early signal of disease activity.

“CancerMRD bridges a critical information gap in oncology by switching monitoring to a molecular level. Where imaging reaches its limits, CancerMRD detects subtle changes in ctDNA and redefines how tumor burden is monitored," states Dr. Dr. Saskia Biskup, Managing Director and Co-founder of CeGaT.

Tissue-Informed Approach to Dynamic Insights
CancerMRD integrates three key innovations and benefits, offering a unique and unmatched approach to patient-centric cancer monitoring:
  • personalized approach: The creation of a tumor fingerprint, which is unique to each patient and tumor, forms the baseline for all follow-up monitoring. CancerMRD’s tissue-informed approach leverages state-of-the-art whole genome sequencing (WGS) to identify tumor-specific variants, enabling highly tailored tracking of disease progression.
  • non-invasive monitoring: Subsequent monitoring only requires liquid biopsy and uses the existing fingerprint for comparison. Thus, CancerMRD reduces patient burden as invasive tissue biopsies or radiation exposure can be bypassed.  
  • dynamic insights: Repeatable tests enable continuous assessment of ctDNA levels over time. These provide physicians with dynamic data to adapt therapies and make timely decisions.
Key Applications of CancerMRD
As a powerful tool to monitor overall tumor burden, CancerMRD’s key applications include:
  • observation of changes in disease course: CancerMRD assesses the impact of therapy on patients with stable disease and low tumor burden, enabling necessary adjustments. Additionally, CancerMRD can detect tumor regression.
  • early detection of relapse: Our service identifies recurrence at a molecular level, which is especially important for patients in remission. If CancerMRD detects a relapse, it allows for prompt intervention.
Strengthening CeGaT‘s Tumor Diagnostics Portfolio
CancerMRD complements CeGaT’s comprehensive tumor diagnostics portfolio as a monitoring service for long-term tracking of the overall tumor burden. CeGaT also offers CancerDetect® as a monitoring tool: It is a highly sensitive hotspot mutation-centered panel that can be used for cases where knowing a specific variant's presence is crucial.  For example, this includes cases where the variant serves as a drug target or when tracking the emergence of resistance mutations over time. 

For more information and detailed insights into the new service, please visit our website.

CeGaT GmbH

CeGaT GmbH, founded in Tübingen, Germany, in 2009, is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations, driving science forward with own findings. The owner-managed company stands for independence, an extensive personal customer service, and premium quality. CeGaT's laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO 17025 and thus meets the highest international standards. To keep the responsibility for the whole project, and to maintain the best results, CeGaT carries out all steps in-house and under scientific supervision.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2025, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.